Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.
Saved in:
| Title: | Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study. |
|---|---|
| Authors: | Schmedt N; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Alhamdow A; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Tskhvarashvili G; IQVIA, Tallinn, Estonia., Saarelainen L; IQVIA, Espoo, Finland., Qiao X; IQVIA, Espoo, Finland., Lobier M; IQVIA, Espoo, Finland., Hoti F; IQVIA, Espoo, Finland. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Aug; Vol. 27 (8), pp. 4401-4414. Date of Electronic Publication: 2025 Jun 13. |
| Publication Type: | Comparative Study; Journal Article; Multicenter Study; Observational Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
